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Abstract. Experimental data integrated with results of in silico studies allows to assess 
pharmacokinetic and pharmacodynamic parameters more carefully. 
Сomputer technology permit to model the mechanism of action (molecular docking) and predict 
pharmacokinetic parameters (ADMET profile) based on the physicochemical properties of a small drug 
molecule. An experimental model (in vitro, in vivo) allows to evaluate the effects of a drug molecule on 
a biological model. 
An example of the integration of computer technology and experimental research is a 
comprehensive approach to assessment of toxicity of the antiviral drug riamilovir. The aim of in vivo 
experiment was to simulate the chronic toxicity of riamilovir on non-linear guinea pigs (n = 20), the 
experiment lasted 8 weeks, animals were divided into 4 groups: the control group that didn’t receive the 
drug, and the experimental groups received riamilovir in terms of the human equivalent dose (HED) 10 
mg/kg, 20 mg/kg, 30 mg/kg. Liver histology samples showed macrovacuole steatosis in the experimental 
groups and decrease in cholesterol level in the group with HED = 20 mg/kg. 
According to molecular docking data it was found that riamilovir is a potential inhibitor of the 
HSP90  protein [1], which is involved in lipid metabolism [2]. As a result of compiling the ADMET 
profile was detected that the subcellular location of riamilovir is inside the mitochondria. According to 
the literature, inhibition of the HSP90  protein leads to a decrease in cholesterol level and deformation 
of the mitochondrial architecture with a corresponding increase in the number of reactive oxygen species 
[3]. Oxidative stress is one of the pathogenetic mechanisms of the development of macrovacuole steatosis 
[4]. 
Thus, various types of studies complement each other and allow, based on the physicochemical 
properties of drug molecules, to interpret the data of experimental studies. 
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